NEURO2024

講演情報

ポスター

F. 精神疾患の基礎と臨床

[3P] 62 統合失調症

2024年7月26日(金) 13:50 〜 14:50 ポスター会場 (マリンメッセ福岡 B館)

[3P-244] Genome-wide DNA methylation risk scores for schizophrenia derived from blood and brain tissues further explain the genetic risk in patients stratified by polygenic risk scores for schizophrenia and bipolar disorder

*大井 一高1,2、Mihoko Shimada3、Midori Soda4、Daisuke Nishizawa5、Daisuke Fujikane1、Kentaro Takai1、Ayumi Kuramitsu1、Yukimasa Muto1、Shunsuke Sugiyama1、Junko Hasegawa5、Kiyoyuki Kitaichi4、Kazutaka Ikeda5、Toshiki Shioiri1 (1. Department of Psychiatry, Gifu University Graduate School of Medicine, 2. Department of General Internal Medicine, Kanazawa Medical University, Ishikawa, Japan, 3. Genome Medical Science Project (Toyama), National Center for Global Health and Medicine (NCGM), Tokyo, Japan, 4. Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan, 5. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan)

キーワード:Epigenome-wide association study, methylation risk score, polygenic risk score, schizophrenia

要旨・抄録、PDFの閲覧には参加者用アカウントでのログインが必要です。参加者ログイン後に閲覧・ダウンロードできます。
» 参加者用ログイン